| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| CTT |
|
C52H73N13O14S2 |
1168.34 |
H2N-CTTHWGFTLC-OH |
H2N-Cys-Thr-Thr-His-Trp-Gly-Phe-Thr-Leu-Cys-OH |
10 |
MMP-9–targeting peptide |
|
| H2009.1 |
|
C90H157N31O30 |
2153.4 |
H2N-RGDLATLRQLAQEDGVVGVR-OH |
H2N-Arg-Gly-Asp-Leu-Ala-Thr-Leu-Arg-Gln-Leu-Ala-Gln-Glu-Asp-Gly-Val-Val-Gly-Val-Arg-OH |
20 |
αvβ6 integrin–targeting peptide |
|
| EHGAMEI |
|
C32H51N9O12S1 |
785.87 |
H2N-EHGAMEI-OH |
H2N-Glu-His-Gly-Ala-Met-Glu-Ile-OH |
7 |
EGFR-targeting peptide |
|
| p160 |
|
C74H105N17O17S1 |
1536.79 |
H2N-VPWMEPAYQRFL-OH |
H2N-Val-Pro-Trp-Met-Glu-Pro-Ala-Tyr-Gln-Arg-Phe-Leu-OH |
12 |
Keratin-1–targeting peptide |
|
| GTI |
|
C12H23N3O5 |
289.33 |
H2N-GTI-OH |
H2N-Gly-Thr-Ile-OH |
3 |
Prostate-specific membrane antigen–targeting peptide |
|
| P1 |
|
C76H97N17O16 |
1504.69 |
H2N–HLWGWLYAPSFQ–OH |
H2N–His–Leu–Trp–Gly–Trp–Leu–Tyr–Ala–Pro–Ser–Phe–Gln–OH |
12 |
Galectin-1–targeting peptide |
|
| CPGPEGAGC |
|
C30H45N9O12S2 |
787.86 |
H2N-CPGPEGAGC-OH |
H2N-Cys-Pro-Gly-Pro-Glu-Gly-Ala-Gly-Cys-OH |
9 |
Aminopeptidase P–targeting peptide |
|
| YCDGFYACYMDV |
|
C65H85N13O19S3 |
1448.64 |
H2N-YCDGFYACYMDV-NH2 |
H2N-Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val-NH2 |
12 |
HER-2–targeting peptide |
|
| HAIYPRH |
|
C41H60N14O9 |
893 |
H2N-HAIYPRH-OH |
H2N-His-Ala-Ile-Tyr-Pro-Arg-His-OH |
7 |
TfR-targeting peptide |
|
| HTMYYHHYQHHL |
|
C77H99N23O18S1 |
1666.82 |
H2N-HTMYYHHYQHHL-OH |
H2N-His-Thr-Met-Tyr-Tyr-His-His-Tyr-Gln-His-His-Leu-OH |
12 |
VEGFR-targeting peptide |
|
| IL4RPep-1 |
|
C44H82N20O13S2 |
1163.38 |
H2N-CRKRLDRNC-OH |
H2N-Cys-Arg-Lys-Arg-Leu-Asp-Arg-Asn-Cys-OH |
9 |
IL-4R–targeting peptide |
|
| E5 |
|
C113H181N39O31S1 |
2613.95 |
H2N-GGRSFFLLRRIQGCRFRNTVDD-OH |
H2N-Gly-Gly-Arg-Ser-Phe-Phe-Leu-Leu-Arg-Arg-Ile-Gln-Gly-Cys-Arg-Phe-Arg-Asn-Thr-Val-Asp-Asp-OH |
22 |
CXCR4-targeting peptide |
|
| MDDRWPLEYTDDTYEIPW |
|
C107H145N23O35S1 |
2345.49 |
H2N-MDDRWPLEYTDDTYEIPW-OH |
H2N-Met-Asp-Asp-Arg-Trp-Pro-Leu-Glu-Tyr-Thr-Asp-Asp-Thr-Tyr-Glu-Ile-Pro-Trp-OH |
18 |
B16 melanoma–targeting peptide |
|
| WMW10 |
|
C60H88N16O16S1 |
1321.5 |
H2N-WMWVTNLRTD-OH |
H2N-Trp-Met-Trp-Val-Thr-Asn-Leu-Arg-Thr-Asp-OH |
10 |
DLC1 protein–targeting peptide |
|
| v6 |
|
C27H36N8O10 |
632.62 |
H2N-NEWQG-OH |
H2N-Asn-Glu-Trp-Gln-Gly-OH |
5 |
CD44v6 receptor–targeting peptide |
|
| SKPPGTSS |
|
C31H53N9O13 |
759.81 |
H2N-SKPPGTSS-OH |
H2N-Ser-Lys-Pro-Pro-Gly-Thr-Ser-Ser-OH |
8 |
Stem cell–targeting peptide; |
|
| P7 |
|
C68H99N19O18 |
1470.63 |
H2N–YSWHIDIVAPRN–OH |
H2N–Tyr–Ser–Trp–His–Ile–Asp–Ile–Val–Ala–Pro–Arg–Asn–OH |
12 |
Galectin-1–targeting peptide |
|
| FHT |
|
C63H93N19O18 |
1404.53 |
H2N-FHTPSQNSAFRL-OH |
H2N-Phe-His-Thr-Pro-Ser-Gln-Asn-Ser-Ala-Phe-Arg-Leu-OH |
12 |
Circulating tumor homing cell–targeting peptide |
|
| Pep-20 |
|
C74H93N21O18 |
1564.66 |
H2N-AWSATWSNYWRH-OH |
H2N-Ala-Trp-Ser-Ala-Thr-Trp-Ser-Asn-Tyr-Trp-Arg-His-OH |
12 |
CD47-targeting peptide |
|
| B6 |
|
C45H80N18O11S1 |
1081.3 |
H2N-CGHKAKGPRK-OH |
H2N-Cys-Gly-His-Lys-Ala-Lys-Gly-Pro-Arg-Lys-OH |
10 |
Transferrin receptor–targeting peptide |
|